GSK vet Carlo Russo is joining up with some of his former gene therapy colleagues, taking the chief medical officer’s role at Milan-based Genenta Science.
Russo is coming over directly from Adverum, but earlier worked at GSK as head of R&D for their rare disease unit. Russo and Genenta co-founder Luigi Naldini had crossed paths before at the San Raffaele Hospital in Milan, a pioneer in gene therapy. A collaboration between San Raffaele and GSK led to the approval of Strimvelis last year, which is looking to become used in Europe for a rare disease called ADA-SCID (severe combined immunodeficiency due to adenosine deaminase deficiency.)
Genenta’s tech focuses on a gene transfer strategy into autologous hematopoietic stem cells to target anti-tumor proteins to tumor-infiltrating monocytes/macrophages.
Strimvelis was not the first gene therapy to win a European OK. That was won by uniQure’s Glybera, which is essentially unused. In the US, Spark gets credit as a leader in the field, which is working to land the first OK in the field in this region.
“(Russo) contributed to the marketing authorization of the first ever ex-vivo gene therapy (Strimvelis),” said Genenta CEO and co-founder Pierluigi Paracchi. “We see a great scientific and clinical potential in this reunion, we see the opportunity to reach the same outstanding results.”
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,500+ biopharma pros who read Endpoints News by email every day.Free Subscription